NEW YORK (GenomeWeb News) â€" In a pair of papers appearing online today in the Lancet and Lancet Oncology, members of the Breast Cancer Intergroup of North America reported that some post-menopausal, estrogen receptor positive breast cancer patients benefit from the addition of chemotherapy to standard tamoxifen treatment.

And, the researchers found, the addition of chemotherapy was most beneficial for individuals scoring high on Genomic Health's Oncotype DX test, suggesting the recurrence assay may be helpful for guiding such treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.